Abstract
AbstractSARS-CoV-2 infection results in wide-ranging disease manifestation from asymptomatic to potentially lethal. Infection poses an increased threat of severity to at-risk populations including those with hypertension, diabetes, and obesity. Type 2 Diabetes (T2DM), is characterized, in part, by insulin insensitivity and impaired glucose regulation. T2DM patients have increased disease severity and poorer outcomes with COVID-19. We utilized the diet-induced obesity (DIO) model of Type 2 Diabetes in SARS-CoV-2-susceptible K18-hACE2 transgenic mice to better understand the obesity co-morbidity. Female DIO, but not male DIO mice challenged with SARS-CoV-2 were observed to have shortened time to morbidity compared to normal diet mice. Increase in susceptibility to SARS-CoV2 in female DIO was associated with increased total viral RNA burden compared to male mice. RNAseq analysis was performed on the lungs of non-challenged, challenged, females, males, of either normal diet or DIO cohorts to determine the disease specific transcriptional profiles. DIO female mice had more total activated genes than normal diet mice after challenge; however, male mice experienced a decrease. GO term analysis revealed the DIO condition increased interferon response signatures and interferon gamma production following challenge. Male challenged mice had robust expression of antibody-related genes suggesting antibody producing cell localization in the lung. DIO reduced antibody gene expression in challenged males. Collectively this study establishes a preclinical T2DM/obesity co-morbidity model of COVID-19 in mice where we observed sex and diet specific responses that begin to explain the effects of obesity and diabetes on COVID-19 disease.
Publisher
Cold Spring Harbor Laboratory
Reference101 articles.
1. Comorbidity and its Impact on Patients with COVID-19;Sn Compr Clin Med [Internet,2020
2. Djaharuddin I , Munawwarah S , Nurulita A , Ilyas M , Tabri NA , Lihawa N . Comorbidities and mortality in COVID-19 patients. Gac Sanit [Internet]. 2021 Jan 1 [cited 2022 Mar 11];35 Suppl 2:S530–2. Available from: https://pubmed.ncbi.nlm.nih.gov/34929892/
3. Ng WH , Tipih T , Makoah NA , Vermeulen JG , Goedhals D , Sempa JB , et al. Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. MBio [Internet]. 2021 Jan 1 [cited 2022 Mar 29];12(1):1–12. Available from: https://journals.asm.org/doi/full/10.1128/mBio.03647-20
4. Centers of Diseases and Control. People with Certain Medical Conditions. Centers Dis Control Prev [Internet]. 2021 [cited 2022 Mar 11];1–6. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
5. Klein SL , Flanagan KL. Sex differences in immune responses. Nat Publ Gr [Internet]. 2016 [cited 2022 Mar 11]; Available from: www.nature.com/nri
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献